Eleven infants with RDS, 6 treated with intravenous fluids and 5 treated with intravenous fluids plus SKA fibrinolysin, are presented. The mortality rates were 17% (1/6) in the group receiving only intravenous fluids and 100% (5/5) in the group receiving intravenous fluids and intravenous SKA fibrinolysin. Combining the 8 infants treated with intravenous SKA fibrinolysin reported by Ambrus et al. with the present series, a mortality rate of 87% (11/13) was obtained. The intravenous administration of SKA fibrinolysin would appear to be contraindicated in the treatment of RDS in premature infants since its use has been associated with a significantly increased mortality rate—a mortality rate which makes the risk of further trials highly prohibitive.

This content is only available via PDF.
You do not currently have access to this content.